Board of Directors

Board of Directors

Chairman and Chief Executive Officer
JFC
John F. Crowley is the Chairman and CEO of Amicus Therapeutics, Inc.  John's involvement with biotechnology stems from the 1998 diagnosis of two of his children with Pompe disease-a severe and often fatal neuromuscular disorder. In his drive to find a cure for them, he left his position at
Lead Independent Director
HAYDEN
From 1981-2006, Mr. Hayden had a highly-successful 25 year career in pharmaceuticals and related health care businesses with Bristol-Myers Squibb Company. Since March of 2006, Mr. Hayden has held key leadership roles at several venture-stage pharmaceutical and biotech companies.
Managing Director, SJ Barer Consulting, LLC
Dr. Barer is the Managing Director of SJ Barer Consulting, LLC. He served as Chairman of Celgene Corporation from January 2011 to June 2011 and as Executive Chairman from June 2010 to January 2011. From January 2006 to June 2010, he served as Chief Executive Officer of Celgene, and also as Chairman
Senior Advisor, The Carlyle Group
Mr. Essner is Senior Advisor to the global healthcare group at The Carlyle Group, a global private equity firm. Mr. Essner retired as Chairman and Chief Executive Officer of Wyeth, now part of Pfizer, in 2008. During his 32-year career in the pharmaceutical industry, he held several prominent
Chief Executive Officer, Global Blood Therapeutics
TED
Dr. Love is Chief Executive Officer of Global Blood Therapeutics, a biopharmaceutical company developing novel, orally available small molecule therapeutics for the treatment of severe chronic blood diseases. From February 2010 to August 2012, Dr. Love served as Executive Vice President and Head of
President & Chief Executive Officer, International AIDS Vaccine Initiative
MARGIE
Margaret G. McGlynn is President and CEO of the International AIDS Vaccine Initiative (IAVI), a global not-for-profit organization whose mission is to ensure the development of safe, effective, accessible, preventive HIV vaccines for use throughout the world.
Chief Executive Officer and Chairman, Ardelyx
Mr. Raab has been Chief Executive Officer and Chairman of Ardelyx since March 2009. He previously was a partner at NEA from 2002 and specialized in healthcare investments focusing on biotechnology and pharmaceutical sectors. Mr. Raab is also a member of the Healthcare Advisory Board of the
President & Chief Financial Officer, The Medicines Company
Mr. Sblendorio acts as Chair of the audit committee. He currently serves as the President and Chief Financial Officer for The Medicines Company. Prior to joining The Medicines Company, Mr. Sblendorio was Executive Vice President and Chief Financial Officer of Eyetech Pharmaceuticals, Inc.